Filtered By:
Infectious Disease: Tuberculosis
This page shows you your search results in order of date. This is page number 8.
Order by Relevance | Date
Total 482 results found since Jan 2013.
Lung Effects of Household Air Pollution
J Allergy Clin Immunol Pract. 2022 Sep 2:S2213-2198(22)00869-8. doi: 10.1016/j.jaip.2022.08.031. Online ahead of print.ABSTRACTBiomass fuel smoke, secondhand smoke, and oxides of nitrogen are common causes of household air pollution (HAP). Almost 2.4 billion people worldwide use solid fuels for cooking and heating, mostly in low- and middle-income countries. Wood combustion for household heating is also common in many areas of high-income countries, and minorities are particularly vulnerable. HAP in low- and middle-income countries is associated with asthma, acute respiratory tract infections in adults and children, chroni...
Source: Clinical Lung Cancer - September 5, 2022 Category: Cancer & Oncology Authors: Anna Y Qiu Shuguang Leng Meredith McCormack David B Peden Akshay Sood Source Type: research
Anthony Fauci, loved and hated, plots his next move: ‘I'm not going to sit in my house’
In 1984, when Anthony Fauci took over as head of the National Institute of Allergy and Infectious Diseases (NIAID), his wife gave him a plant for the new office. Both the palm and the 81-year-old physician are still there, the giant plant now crowding the office of one of the most celebrated—and polarizing—scientific figures in U.S. history. But not for much longer. Fauci announced on 22 August that he would step down at the end of the year from both NIAID and his post as the chief medical adviser to President Joe Biden.
“What am I going to do with this plant? It’s a monster. I can’t fit it in any other plac...
Source: ScienceNOW - September 1, 2022 Category: Science Source Type: news
Anthony Fauci, loved and hated, plots his next move: ‘I’m not going to sit in my house’
In 1984, when Anthony Fauci took over as head of the National Institute of Allergy and Infectious Diseases (NIAID), his wife gave him a plant for the new office. Both the palm and the 81-year-old physician are still there, the giant plant now crowding the office of one of the most celebrated—and polarizing—scientific figures in U.S. history. But not for much longer. Fauci announced on 22 August that he would step down at the end of the year from both NIAID and his post as the chief medical adviser to President Joe Biden.
“What am I going to do with this plant? It’s a monster. I can’t fit it in any other plac...
Source: ScienceNOW - September 1, 2022 Category: Science Source Type: news
PAN-TB Collaboration to Advance Investigational Tuberculosis Drug Regimens to Phase 2 Clinical Trials
August 17, 2022 – The Project to Accelerate New Treatments for Tuberculosis (PAN-TB) collaboration announced today the execution of a joint development agreement (JDA) supporting the progression of two investigational tuberculosis (TB) combination treatment regimens into phase 2 clinical development. The collaboration will evaluate whether the novel regimens, which combine registered products and new chemical entities (NCEs), can effectively treat all forms of active pulmonary TB using substantially shorter treatment durations than existing drug regimens, with the goal of identifying a regimen suitable for phase 3 develo...
Source: Johnson and Johnson - August 17, 2022 Category: Pharmaceuticals Source Type: news
STELARA ® (ustekinumab) Approved by the U.S. Food and Drug Administration to Treat Pediatric Patients with Active Psoriatic Arthritis
HORSHAM, PENNSYLVANIA, August 1, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the U.S. Food and Drug Administration (FDA) has approved STELARA® (ustekinumab) for the treatment of pediatric patients six years of age and older with active psoriatic arthritis (PsA). This rare disease that resembles adult PsA affects five to eight percent of children and adolescents with chronic inflammatory arthritis.*1-7 Two of the four indications for STELARA now include pediatric patients, further expanding its treatment profile since the first approval in 2009 for adults living with moderate...
Source: Johnson and Johnson - August 1, 2022 Category: Pharmaceuticals Tags: Latest News Source Type: news
As pandemics collide, push to end AIDS stumbles
The world’s response to the 5-decade-old HIV/AIDS pandemic is faltering badly in the face of declines in spending and the COVID-19 pandemic, according to annual update from the Joint United Programme on HIV/AIDS (UNAIDS). “The data we are sharing today bring painful but vital news,” said the director of UNAIDS, Winnie Byanyima, at a press conference yesterday to discuss the release of the update. “The response to the AIDS pandemic has been derailed by a global crisis from the colliding pandemics.”
UNAIDS issued the lengthy report, titled
In Danger: UNAIDS Global AIDS Update 2022
, as a run up to the 24...
Source: Science of Aging Knowledge Environment - July 28, 2022 Category: Geriatrics Source Type: research
Janssen Presents Study Results Showing Clinical Efficacy for TREMFYA ® (guselkumab) and Long-Term Safety Profile for STELARA® (ustekinumab) for Patients Living with Inflammatory Bowel Disease at Digestive Disease Week® 2022
SPRING HOUSE, PENNSYLVANIA, May 24, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new data from the Phase 2 GALAXI 1 clinical trial of TREMFYA® (guselkumab) in adult patients with moderately to severely active Crohn’s disease (CD), and from three separate long-term pooled analyses of adult patients with ulcerative colitis (UC) and CD treated with STELARA® (ustekinumab).1,2,3,4 These data are being presented as oral and poster presentations and are among 29 Janssen abstracts presented during the Digestive Disease Week® (DDW) meeting taking place in person and virtually in San Di...
Source: Johnson and Johnson - May 24, 2022 Category: Pharmaceuticals Source Type: news
Asthma and COVID-19 risk: a systematic review and meta-analysis
Background
Individual case series and cohort studies have reported conflicting results in people with asthma on the vulnerability to and risk of mortality from coronavirus disease 2019 (COVID-19).
Research question
Are people with asthma at a higher risk of being infected or hospitalised or poorer clinical outcomes from COVID-19?
Methods
A systematic review and meta-analysis based on five main databases including the World Health Organization COVID-19 database between 1 December 2019 and 11 July 2021 on studies with a control (non-asthma) group was conducted. Prevalence and risk ratios were pooled using Sidik–Jonkm...
Source: European Respiratory Journal - March 31, 2022 Category: Respiratory Medicine Authors: Sunjaya, A. P., Allida, S. M., Di Tanna, G. L., Jenkins, C. R. Tags: Asthma and allergy, Respiratory infections and tuberculosis Original Articles: Asthma and infection Source Type: research
First patient in the Iranian Registry with novel DOCK2 gene mutation, presenting with skeletal tuberculosis, and review of literature
Dedicator of cytokinesis 2 (DOCK2) deficiency is an inborn error of immunity characterized by cellular and humoral immunological abnormalities leading to early-onset infections.
Source: Allergy, Asthma and Clinical Immunology - December 6, 2021 Category: Allergy & Immunology Authors: Niusha Sharifinejad, Homa Sadri, Arash Kalantari, Samaneh Delavari, Amirhosein Noohi, Yasaman Aminpour, Araz Sabzevari and Gholamreza Azizi Tags: Case Report Source Type: research
Does parental tuberculosis infection increase the risk of asthma in their offspring? A Norwegian registry-based study
Conclusions: Parental tuberculosis infection in childhood was associated with higher risk of asthma in their future offspring. We speculate that tuberculosis may have profound impact that may be transferred to offspring, the nature of such impact needs further study.
Source: European Respiratory Journal - November 25, 2021 Category: Respiratory Medicine Authors: Lopez-Cervantes, J. P., Shigdel, R., Mustafa, T., Svanes, C. Tags: Allergy and immunology Source Type: research
Janssen Reports Positive Topline Week 48 Phase 2 Results for TREMFYA ® (guselkumab) in Adults With Moderately to Severely Active Crohn's Disease
SPRING HOUSE, PENNSYLVANIA, November 17, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced topline results from the Phase 2 GALAXI 1 clinical trial which showed rates of clinical remission (Crohn’s Disease Activity Index [CDAI]<150) previously reported at week 12 increased at week 48 among adults with moderately to severely active Crohn’s disease (CD) treated with TREMFYA® (guselkumab).1 At week 48, 65 percent of patients receiving TREMFYA achieved clinical remission. TREMFYA is under investigation and not currently approved for the treatment of CD in the U.S.2Janssen previously...
Source: Johnson and Johnson - November 17, 2021 Category: Pharmaceuticals Source Type: news
M009 a case of atypical delayed anaphylaxis to rifampin
We report on an unusual case of delayed anaphylactic shock to rifampin occurring many days after initiation of therapy.
Source: Annals of Allergy, Asthma and Immunology - November 1, 2021 Category: Allergy & Immunology Authors: C. Nguyen, P. Mohyi, K. Kwong Source Type: research
New Analyses Suggest Favorable Results for STELARA ® (ustekinumab) When Used as a First-Line Therapy for Bio-Naïve Patients with Moderately to Severely Active Crohn’s Disease and Ulcerative Colitis
SPRING HOUSE, PENNSYLVANIA, October 25, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced data from two new analyses of STELARA® (ustekinumab) for the treatment of adults with moderately to severely active Crohn’s disease (CD) and ulcerative colitis (UC).1,2 In a modelled analysisa focused on treatment sequencing using data from randomized controlled trials, network meta-analysis and literature, results showed patient time spent in clinical remission or response was highest when STELARA was used as a first-line advanced therapy for bio-naïve patients with moderately to severely acti...
Source: Johnson and Johnson - October 25, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
BCG vaccine ’s off-target effects on allergic, inflammatory, and autoimmune diseases: Worth another shot?
Allergy is an exaggerated immune response to foreign antigens resulting from a combination of genetic, epigenetic and environmental interactions. Immune responses misdirected against intrinsic antigens can lead to autoimmunity. The incidence of allergic and autoimmune diseases is rising, constituting a global public health challenge with broad socioeconomic implications. The Bacille Calmette-Gu érin (BCG) vaccine is a live attenuated Mycobacterium bovis vaccine given to millions of newborns worldwide to prevent tuberculosis.
Source: Journal of Allergy and Clinical Immunology - October 18, 2021 Category: Allergy & Immunology Authors: Asimenia Angelidou, Laure F. Pittet, Denise Faustman, Nigel Curtis, Ofer Levy Tags: Paradigms and perspectives Source Type: research
Janssen Submits Application Seeking U.S. FDA Approval of STELARA ® (ustekinumab) for the Treatment of Pediatric Patients With Juvenile Psoriatic Arthritis
HORSHAM, PENNSYLVANIA, October 8, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the submission of a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) seeking expanded approval of STELARA® (ustekinumab) to treat pediatric patients ages 5 years and older with juvenile psoriatic arthritis (jPsA).The filing is supported by extrapolation of data from nine studies across both adult trials in active PsA and adult and pediatric studies in moderate to severe plaque psoriasis, totaling 3,997 patients evaluated across these closely associated dis...
Source: Johnson and Johnson - October 8, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
